Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Colonic Neoplasms 1

Interventions

pembrolizumab 139Cisplatin 76Cetuximab 53Carboplatin 49Paclitaxel 39Nivolumab 39Radiotherapy 37Docetaxel 34Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 25Specimen Handling 20Fluorouracil 20Platinum 141,2-diaminocyclohexaneplatinum II citrate 13Taxes 12cemiplimab 11Radiation 11Ipilimumab 11atezolizumab 10Surgical Procedures, Operative 10Drug Therapy 10tislelizumab 9Biopsy 9durvalumab 8Radiosurgery 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8Standard of Care 7Chemoradiotherapy 7Immune Checkpoint Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × CIMAvax EGF × 1 year × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡